New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance

International Journal of Antimicrobial Agents

Volumn 39, Issue 2, 2012, Pages 96-104

  Gould, Ian M ^a   David, Michael Z ^b   Esposito, Silvano ^c   Garau, Javier ^d   Lina, Gerard ^e   Mazzei, Teresita ^f   Peters, Georg ^g  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF CHICAGO   (United States)

^c Dipartimento di Medicina Pubblica Clinica e Preventiva   (Italy)

^d HOSPITAL MÚTUA DE TERRASSA   (Spain)

^e UNIVERSITÉ DE LYON   (France)

^f Department of Preclinical and Clinical Pharmacology ^*  (Italy)

^g Institute of Medical Microbiology   (Germany)

Author keywords

Drug resistance; Meticillin resistant Staphylococcus aureus; Pneumonia; Staphylococcal skin infections; Virulence

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; AZTREONAM PLUS VANCOMYCIN; CARBAPENEM; CEFTAROLINE FOSAMIL; CEFTAZIDIME; CHLORAMPHENICOL PLUS FLORFENICOL; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; METICILLIN; NEMONOXACIN; OMADACYCLINE; ORITAVANCIN; PANTON VALENTINE LEUKOCIDIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; RIFAPRIM; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

ACUTE KIDNEY FAILURE; ANEMIA; ANTIBIOTIC RESISTANCE; BACTERIAL ENDOCARDITIS; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; HYPOKALEMIA; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); MULTIPLE ORGAN FAILURE; NEPHROTOXICITY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SPECIES DIFFERENCE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UPREGULATION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84855484682     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.09.028     Document Type: Short Survey

References (101)

1. European Centre for Disease Prevention and Control/European Medicines Agency (ECDC/EMEA). Technical report. The bacterial challenge: time to react. Stockholm, Sweden: ECDC/EMEA; 2009. http://ecdc.europa.eu/en/publications/ Publications/0909 TER The Bacterial Challenge Time to React. pdf [accessed 21.07.11].
2. European Centre for Disease Prevention and Control (ECDC). Annual epidemiological report on communicable diseases in Europe 2009. Stockholm, Sweden: ECDC; 2010. http://www.ecdc.europa.eu/en/publications/Publications/0910 SUR Annual Epidemiological Report on Communicable Diseases in Europe.pdf [accessed 14.06.11].
3. de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 2011;55:1598-605.
4. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-9. (Pubitemid 36099097)
5. Shurland S, Zhan M, Bradham DD, Roghmann MC. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 2007;28:273-9. (Pubitemid 46480725)
6. Athanassa Z, Siempos II, Falagas ME. Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review. Eur Respir J 2008;28:625-32.
7. Skov RL, Jensen KS. Community-associated meticillin-resistant Staphylococcus aureus as a cause of hospital-acquired infections. J Hosp Infect 2009;73:364-70.
8. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010;23:616-87.
9. Valsesia G, Rossi M, Bertschy S, Pfyffer GE. Emergence of SCCmec type IV and SCCmec type V methicillin-resistant Staphylococcus aureus containing the Panton-Valentine leukocidin genes in a large academic teaching hospital in central Switzerland: external invaders or persisting circulators? J Clin Microbiol 2010;48:720-7.
10. International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC). Classification of staphylococcal cassette chromosome mec (SCCmec): guidelines for reporting novel SCCmec elements. Antimicrob Agents Chemother 2009;53:4961-7.
11. McDougal LK, Fosheim GE, Nicholson A, Bulens SN, Limbago BM, Shearer JE, et al. Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States. Antimicrob Agents Chemother 2010;54:3804-11.
12. Li S, Skov RL, Han X, Larsen AR, Larsen J, Sørum M, et al. Novel types of staphylococcal cassette chromosome mec elements identified in clonal complex 398 methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2011;55:3046-50.
13. Garau J, Bouza E, Chastre J, Gudiol F, Harbarth S. Management of methicillin-resistant Staphylococcus aureus infections. Clin Microbiol Infect 2009;15:125-36.
14. Gould IM, Cauda R, Esposito S, Gudiol F, Mazzei T, Garau J. Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? Int J Antimicrob Agents 2011;37:202-9.
15. Kuehnert MJ, Kruszon-Moran D, Hill HA, McQuillan G, McAllister SK, Fosheim G, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 2006;193:172-9. (Pubitemid 43113478)
16. Lina G, Piémont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128-32. (Pubitemid 30265628)
17. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002;359:753-9. (Pubitemid 34215075)
18. Bocchini CE, Hulten KG, Mason Jr EO, Gonzalez BE, Hammerman WA, Kaplan SL. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics 2006;117:433-40. (Pubitemid 46071606)
19. Löffler B, Hussain M, Grundmeier M, Brück M, Holzinger D, Varga G, et al. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog 2010;6:e1000715.
20. Lipinska U, Hermans K, Meulemans L, Dumitrescu O, Badiou C, Duchateau L, et al. Panton-Valentine leukocidin does play a role in the early stage of Staphylococcus aureus skin infections: a rabbit model. PLoS ONE 2011;6:e22864.
21. Crémieux AC, Dumitrescu O, Lina G, Vallee C, Côté JF, Muffat-Joly M, et al. Panton-Valentine leukocidin enhances the severity of community-associated methicillin-resistant Staphylococcus aureus rabbit osteomyelitis. PLoS ONE 2009;4:e7204.
22. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, et al. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci USA 2010;107:5587-92.
23. Hirschhausen N, Schlesier T, Schmidt MA, Götz F, Peters G, Heilmann C. A novel staphylococcal internalization mechanism involves the major autolysin Atl and heat shock cognate protein Hsc70 as host cell receptor. Cell Microbiol 2010;12:1746-64.
24. Grundmeier M, Tuchscherr L, Brück M, Viemann D, Roth J, Willscher E, et al. Staphylococcal strains vary greatly in their ability to induce an inflammatory response in endothelial cells. J Infect Dis 2010;201:871-80.
25. Tuchscherr L, Löffler B, Buzzola FR, Sordelli DO. Staphylococcus aureus adaptation to the host and persistence: role of loss of capsular polysaccharide expression. Future Microbiol 2010;5:1823-32.
26. Tuchscherr L, Medina E, Hussain M, Völker W, Heitmann V, Niemann S, et al. Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection. EMBO Mol Med 2011;3:129-41.
27. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-55.
28. Gould FK, Brindle R, Chadwick PR, Fraise AP, Hill S, Nathwani D, et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 2009;63:849-61.
29. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or β- lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8:53-66. (Pubitemid 351620940)
30. Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2010;35:3-12.
31. Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, Rupp ME. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010;38:1802-8.
32. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011;139:1148-55.
33. Kunkel M, Chastre JE, Kollef M, Niederman M, Shorr AF, Wunderink RG, et al. Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus. In: Infectious Diseases Society of America (IDSA) 48th annual meeting. 2010 [Abstract LB-49].
34. Dodds TJ, Hawke CI. Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis). ANZ J Surg 2009;79:629-35.
35. Bounthavong M, Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr Med Res Opin 2010;26:407-21.
36. Logman JF, Stephens J, Heeg B, Haider S, Cappelleri J, Nathwani D, et al. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr Med Res Opin 2010;26:1565-78.
37. Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2010;199:804-16.
38. Novartis. Cubicin. Summary of product characteristics. Novartis; 2006.
39. Rehm SJ, Boucher H, Levine D, Campion M, Eisenstein BI, Vigliani GA, et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 2008;62:1413-21.
40. Chaftari AM, Hachem R, Mulanovich V, Chemaly RF, Adachi J, Jacobson K, et al. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 2010;36:182-6.
41. Seaton RA, Daptomycin:. rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother 2008;62(Suppl. 3):iii15-23.
42. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann Pharmacother 2009;43:1211-9.
43. sm). In: 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)/27th International Congress on Chemotherapy (ICC). 2011 [Abstract P1538].
44. Bassetti M, Nicco E, Ginocchio F, Ansaldi F, de Florentiis D, Viscoli C. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents 2010;36:459-61.
45. Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009;49:177-80.
46. Wyeth Pharmaceuticals Inc. Tygacil. Full prescribing information. Wyeth Pharmaceuticals Inc.; 2010.
47. Wyeth Europa Ltd. Tygacil. Summary of product characteristics. Wyeth Europa Ltd.; 2010.
48. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010;68:140-51.
49. Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011;55:1162-72.
50. European Medicines Agency (EMEA). Questions and answers on the review of Tygacil (tigecycline). Outcome of a renewal procedure. London, UK: EMEA; 2011 [EMA/121925/2011] http://www.ema.europa.eu/docs/en GB/document library/Medicine QA/human/000644/WC500102228.pdf [accessed 21.07.11].
51. Pfizer. Direct healthcare professional communication on increase in mortality in clinical trials of Tygacil® (tigecycline). Pfizer; 2011.
52. Theravance Inc. Vibativ® (telavancin) for injection, for intravenous useinitial U.S. approval: 2009. San Francisco, CA: Theravance Inc.; 2009, http://www.accessdata.fda.gov/drugsatfda docs/label/2009/022110s000lbl.pdf [accessed 27.07.11].
53. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin Infect Dis 2008;46:1683-93. (Pubitemid 351706765)
54. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin Infect Dis 2011;52:31-40.
55. Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (initial authorisation): Vibativ-telavancin. European Medicines Agency; 19 May 2011 [EMA/CHMP/399709/2011] http://www.ema.europa.eu/docs/en GB/document library/Summary of opinion - Initial authorisation/ human/001240/WC500106519.pdf [accessed 26.07.11].
56. Forest Laboratories. Teflaro® prescribing information. Forest Laboratories; 2010.
57. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 1 investigators. CANVAS 1, the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010;65(Suppl. 4):iv41-51.
58. Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 2 investigators. CANVAS 2, the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010;65(Suppl. 4):iv53-65.
59. Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010;51:641-50.
60. European Medicines Agency. Questions and answers on the withdrawal of the marketing authorisation application for Ramvocid (oritavancin). London, UK: EMEA; 24 September 2009 [EMEA/554626/2009].
61. Dunbar LM, Milata J, Fitzpatrick M, Larrison A, McClure T, Wasilewski MM. Efficacy of oritavancin at single or infrequent doses for the treatment of complicated skin and skin-structure infections (Abstract P1849). Clin Microbiol Infect 2009;15(Suppl. 4):S537.
62. Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother 2010;54:1338-42.
63. Li CR, Li Y, Li GQ, Yang XY, Zhang WX, Lou RH, et al. In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone. J Antimicrob Chemother 2010;65:2411-5.
64. Hait H, Arbeit R, Molnar D, Noel GJ, Tanaka SK. In a phase 2 complicated skin and soft tissue infections (cSSTI) trial outcomes assessed early in the course of therapy were consistent with outcomes assessed 10-17 days after completing therapy for patients treated with either omadacycline (OMC; PTK796) or linezolid. In: 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)/27th International Congress of Chemotherapy (ICC). 2011.
65. Schmitz GR, Bruner D, Pitotti R, Olderog C, Livengood T, Williams J, et al. Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection. Ann Emerg Med 2010;56:283-7.
66. Jung YJ, Koh Y, Hong SB, Chung JW, Ho Choi S, Kim NJ, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010;38:175-80.
67. Rybak MJ, Lomaestro BM, Rotscahfer JC, Moellering RC, Craig WA, Billeter M, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-7.
68. Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 2008;52:2244-6. (Pubitemid 351758569)
69. Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008;52:269-78.
70. Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int J Antimicrob Agents 2011;37:219-24.
71. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008;46:668-74. (Pubitemid 351321548)
72. Finks J, Wells E, Dyke TL, Husain N, Plizga L, Heddurshetti R, et al. Vancomycin-resistant Staphylococcus aureus, Michigan, USA 2007. Emerg Infect Dis 2009;15:943-5.
73. Saha B, Singh AK, Ghosh A, Bal M. Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J Med Microbiol 2008;57:72-9.
74. Aligholi M, Emaneini M, Jabalameli F, Shahsavan S, Dabiri H, Sedaght H. Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran. Med Princ Pract 2008;17:432-4.
75. Moise PA, Smyth DS, El-Fawal N, Robinson DA, Holden PN, Forrest A, et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008;61:85-90.
76. Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200. (Pubitemid 351269157)
77. Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009;47: 1640-4.
78. Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011;66:1594-9.
79. van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011;55:405-10.
80. Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 2009;63:1050-7.
81. Berthoin K, Ampe E, Tulkens PM, Carryn S. Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. Int J Antimicrob Agents 2009;34:555-60.
82. Gould IM. Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2011;66(Suppl. 4):iv17-21.
83. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004;39:1010-5. (Pubitemid 39313459)
84. Sánchez García M, De la Torre MA, Morales G, Peláez B, Tolón MJ, Domingo S, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010;303:2260-4.
85. Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Peláez B, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010;50:821-5.
86. Camargo IL, Neoh HM, Cui L, Hiramatsu K. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob Agents Chemother 2008;52:4289-99.
87. Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, Yeaman MR, et al. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009;53:2312-8.
88. Sader HS, Becker HK, Moet GJ, Jones RN. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 g/mL isolated in the United States and European hospitals (2006-2008). Diagn Microbiol Infect Dis 2010;66:329-31.
89. Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous- VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 2011;66:1057-60.
90. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
91. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:1079-82. (Pubitemid 43327815)
92. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006;42:1652-3.
93. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering Jr RC, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006;50:1581-5.
94. Yang SJ, Nast CC, Mishra NN, Yeaman MR, Fey PD, Bayer AS. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother 2010;54:3079-85.
95. Gonzalez-Ruiz A, Beiras-Fernandez A, Lehmkuhl H, Seaton RA, Loeffler J, Chaves RL. Clinical experience with daptomycin in Europe: the first 2.5 years. J Antimicrob Chemother 2011;66:912-9.
96. Sakoulas G, Brown J, Lamp KC, Friedrich LV, Lindfield KC. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin Ther 2009;31:1936-45.
97. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005;40:1058-60. (Pubitemid 40418318)
98. Enoch DA, Phillimore N, Karas JA, Horswill L, Mlangeni DA. Relapse of enterococcal prosthetic valve endocarditis with aortic root abscess following treatment with daptomycin in a patient not fit for surgery. J Med Microbiol 2010;59:482-5.
99. Jacobson LM, Milstone AM, Zenilman J, Carroll KC, Arav-Boger R. Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia. Pediatr Infect Dis J 2009;28:445-7.
100. van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient - a review of the literature. Eur J Clin Microbiol Infect Dis 2011;30:603-10.
101. Boyle-Vavra S, Jones M, Gourley BL, Holmes M, Ruf R, Balsam AR, et al. Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure. Antimicrob Agents Chemother 2011;55:2018-25.